These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7885427)

  • 1. Transdermal nicotine as maintenance therapy for ulcerative colitis.
    Thomas GA; Rhodes J; Mani V; Williams GT; Newcombe RG; Russell MA; Feyerabend C
    N Engl J Med; 1995 Apr; 332(15):988-92. PubMed ID: 7885427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal nicotine for active ulcerative colitis.
    Pullan RD; Rhodes J; Ganesh S; Mani V; Morris JS; Williams GT; Newcombe RG; Russell MA; Feyerabend C; Thomas GA
    N Engl J Med; 1994 Mar; 330(12):811-5. PubMed ID: 8114833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis.
    Thomas GA; Rhodes J; Ragunath K; Mani V; Williams GT; Newcombe RG; Russell MA; Feyerabend C
    Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):769-76. PubMed ID: 8864674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial.
    Sandborn WJ; Tremaine WJ; Offord KP; Lawson GM; Petersen BT; Batts KP; Croghan IT; Dale LC; Schroeder DR; Hurt RD
    Ann Intern Med; 1997 Mar; 126(5):364-71. PubMed ID: 9054280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.
    Mantzaris GJ; Sfakianakis M; Archavlis E; Petraki K; Christidou A; Karagiannidis A; Triadaphyllou G
    Am J Gastroenterol; 2004 Jun; 99(6):1122-8. PubMed ID: 15180735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal nicotine for induction of remission in ulcerative colitis.
    McGrath J; McDonald JW; Macdonald JK
    Cochrane Database Syst Rev; 2004 Oct; (4):CD004722. PubMed ID: 15495126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling.
    Sachs DP; Säwe U; Leischow SJ
    Arch Intern Med; 1993 Aug; 153(16):1881-90. PubMed ID: 8110249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis.
    Green JT; Thomas GA; Rhodes J; Evans BK; Russell MA; Feyerabend C; Fuller GS; Newcombe RG; Sandborn WJ
    Clin Pharmacol Ther; 1997 Mar; 61(3):340-8. PubMed ID: 9084459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
    Prantera C; Kohn A; Campieri M; Caprilli R; Cottone M; Pallone F; Savarino V; Sturniolo GC; Vecchi M; Ardia A; Bellinvia S
    Aliment Pharmacol Ther; 2009 Nov; 30(9):908-18. PubMed ID: 19678813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.
    d'Albasio G; Pacini F; Camarri E; Messori A; Trallori G; Bonanomi AG; Bardazzi G; Milla M; Ferrero S; Biagini M; Quaranta S; Amorosi A
    Am J Gastroenterol; 1997 Jul; 92(7):1143-7. PubMed ID: 9219787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial.
    Musch E; Andus T; Malek M; Chrissafidou A; Schulz M
    Z Gastroenterol; 2007 Dec; 45(12):1235-40. PubMed ID: 18080224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
    Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.
    Sinha A; Nightingale J; West KP; Berlanga-Acosta J; Playford RJ
    N Engl J Med; 2003 Jul; 349(4):350-7. PubMed ID: 12878742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
    Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
    Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
    Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study.
    Sandborn WJ; Tremaine WJ; Leighton JA; Lawson GM; Zins BJ; Compton RF; Mays DC; Lipsky JJ; Batts KP; Offord KP; Hurt RD; Green J
    Aliment Pharmacol Ther; 1997 Aug; 11(4):663-71. PubMed ID: 9305473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of transdermal nicotine as an adjunct in smoking cessation therapy. A double-blind randomized study controlled with placebo].
    Daughton DM; Heatley SA; Prendergast JJ; Causey D; Knowles M; Rolf CN; Cheney RA; Hatlelid K; Thompson AB; De Blasio F
    Arch Monaldi Mal Torace; 1992; 47(1-6):17-29. PubMed ID: 1306633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.